The aim of this prospective, randomized and controlled study was to compare the clinical efficacy of intravenous magnesium sulfate (MgSO 4 ) and oral sildenafil therapies with persistent pulmonary hypertension of the newborn. A total of 34 infants in the MgSO 4 group and 31 infants in the sildenafil group completed the study. The time to reach the adequate clinical response [defined as oxygen index (OI) level of <15, a pulmonary artery pressure of <20 mmHg) was significantly shorter in the sildenafil group ( p ¼ 0.002). Duration of mechanical ventilation was longer and the number of the patients requiring inotropic support was higher in the MgSO 4 group ( p ¼ 0.001 and p ¼ 0.002, respectively). Although among two groups the difference in OI > 5 as speculated in our hypothesis could only be found at 36 h of the treatment, sildenafil was more effective than MgSO 4 in the treatment of persistent pulmonary hypertension of the newborns with regard to time to adequate clinical response, duration of mechanical ventilation and support requirement with inotropic agents.
Introduction
Persistent pulmonary hypertension of the newborns (PPHN) is a syndrome characterized by an increased pulmonary vascular resistance, right-to-left shunt and severe hypoxemia without evidence of congenital heart disease [1] . The principal goal of PPHN treatment is selective pulmonary vasodilatation. Various methods of PPHN treatment include: ventilation strategies (high-frequency oscillatory ventilation-HFOV) [2] , pulmonary vasodilators (magnesium [3] , sildenafil [4] , adenosine [5] , bosentan [6] , prostacyclin [7] , tolazolin [8] ) and specific agents [inhaled nitric oxide (iNO)] [9] . Although iNO and ECMO are the gold standards of the PPHN therapy [9, 10] , they are expensive therapy modalities associated with technical difficulties in developing countries. Therefore alternative treatments for PPHN have been evaluated over the past two decades in many studies.
The aim of this study was to determine and compare the clinical efficacy and side effects of intravenous (IV) magnesium sulfate (MgSO 4 ) and oral sildenafil therapy in the newborns with PPHN in a reference center in a developing region of our country without the facilities of iNO, ECMO and HFOV.
Methods
This randomized and prospective study was conducted between 1 February 2007 and 30 April 2008 in the neonatal intensive care unit (NICU) of Diyarbakir Children's Hospital, in Turkey. It is a regional referral NICU. The study was approved by the regional ethics committee and written informed consent was obtained from the parents.
Study design
Eligable neonates were term and near term (35-42 gestational week) newborns, with hypoxemic respiratory failure associated with PPHN. The study entry criteria based on: a pulmonary artery pressure (PAP) of !40 mmHg, an oxygenation index (OI) of !30 (OI ¼ fraction of inspired oxygen Â mean airway pressure/arterial oxygen pressure) and need for mechanical ventilation.
In our study, intravenous MgSO 4 (MgSO 4 group) and oral sildenafil (sildenafil group) were used as vasodilator therapies for PPHN. Exclusion criterias were congenital heart disease, suspicion of sepsis and other anomalies (including congenital diaphragmatic hernia and lung hypoplasia). The newborns in the sildenafil group meeting the pre-set criteria (gastric intolerance or bleeding) were excluded [4, 11] .
Randomization and sample size calculation An independent researcher used a computergenerated randomization table to assign to both groups. A decrease in OI of !5 from the previous calculated value was defined as an improvement in OI. As presented in the study of Baquero et al. [4] , we accepted that a reduction of >10% in OI was significant. For infants with an initial OI value of 30, a decrease of 5 would be a 16.7% effect. Our hypothesis was that one of the vasodilator agent group would have a decrease of 5 in OI level more than the other one. Before the conduction of the study, MgSO 4 was the vasodilator agent used to treat PPHN in our NICU. The retrospective analysis of 11 patients with PPHN who were treated with MgSO 4 yielded a standart deviation of OI as 7.1. On the basis of these findings we calculated that 32 newborns in each group would allow us to obtain a difference of 5 in OI level between groups ( ¼ 0.05, power ¼ 80%, assuming SD ¼ 7.1). The level was set at 0.05 on the basis of a two-sided, two-sample ttest in INSTAT program. It has been estimated that 10% of patients might be dropped out during the study period. Finally sample size was calculated as 36 newborn in each group.
Vasodilator protocol
The MgSO 4 protocol consisted of a loading dose of 200 mg kg À1 infused IV over 30 min followed by a maintenance dose of 20 mg kg À1 h À1 [12] . If the OI did not improve sufficiently, the MgSO 4 infusion rate was increased slowly (10 mg kg À1 h À1 to maximum 100 mg kg À1 h À1 ). When the OI level was <15 and PAP was <20 mmHg, the MgSO 4 infusion was decreased gradually (10 mg kg À1 h
À1
) and terminated in 1 day. Serum magnesium levels were measured daily to maintain the magnesium concentration between 7 and 11 mg dl À1 [13] . A 25-mg tablet of sildenafil was diluated with 25 ml sterile water for final concentration of 1 mg ml
. Dose of solution (0.5 mg kg À1 ) was given via an orogastric tube every 6 h [4] . The dose could be doubled (until reaching a maximum of 2 mg kg
) if the OI did not improve. Sildenafil dose was tapered 50% after reaching the OI level <15 and PAP <20 mmHg and terminated in one day.
Vasodilator treatments have been discontinued in cases when adequate clinical response criteria could not be acquired in 48 h after maximum vasodilator treatment dose is reached.
Data collection
The characteristics of the newborns and monitorized vital signs were recorded. Arterial blood gas samples were collected from umbilical arterial catheter at the beginning of the catheterization and 1, 2, 6 and 12 h after the initiation of the therapy and every 12 h until the end of the vasodilator treatment and ventilatory support. Mean blood pressures (MBP) were maintained in the !50th percentile with inotropic agents (dopamine) [14] . Electrocardiogram and echocardiography were performed daily. Cranial and abdominal ultrasound (US) were performed at the onset of the study, the first and the seventh day and/or after the vasodilator treatment or death. Neurologic and ophtalmological examinations were made after the treatment. Data collector nurse, pediatric cardiologist and ultrasonographer have been masked to the grouping, only the neonatologist who gave medical care to the patients was not blinded to the type of treatment received by the infants.
Time of adequate clinical response [defined as a decrease of PAP to <20 mmHg (improvement of PAP) and OI to <15 (improvement of OI)], duration of mechanical ventilation, support of inotropic agent, mortality rate and side effects were recorded and compared between groups.
Statistical analysis
Data for all cases were analyzed by using the statistical package for social sciences (SPSS 11.5, Chicago, IL) program. The statistical method used in this study was the analysis of variance (ANOVA) for comparison of repeated measurements of OI, PAP and MBP. The other comparisons were performed by t-test, 2 -test and Mann-Whitney U-test. A value of p < 0.05 was considered as significant.
Results
This study was completed with 34 infants in MgSO 4 group and 31 infants in sildenafil group. Participant flow diagram was demonstrated in Fig. 1 . The initial characteristics of the newborns were summarized in Table 1 . The underlying diseases were shown in Table 2 . There was no etiological and characteristic difference between groups. A variety of responses to treatments including time to adequate clinical response, duration of mechanical ventilation, support of inotropic agent and mortality rate were summarized in Table 3 . The time to adequate clinical response was significantly shorter in sildenafil group ( p ¼ 0.002). Duration of mechanical ventilation was longer and the number of patients requiring inotropic support were higher in the MgSO 4 group ( p ¼ 0.001 and p ¼ 0.002, respectively). Three patients with unknown etiologies died (two in the MgSO 4 group and one in the sildenafil group). There was not any difference between groups regarding the mortality rate ( p ¼ 0.96).
OI and PAP values were shown in Figs 2 and 3. The time to the target value for the improvement of the OI (<15) in MgSO 4 and sildenafil group were 60 and 36 h, respectively. In the sildenafil group, the OI was found to be lower after 12 h of the treatment (Fig. 2) . The difference in average OI between groups was found to be >5 only at 36 h of treatment (20.5 AE 8.6 vs. 15.3 AE 7.8). The target value of PAP (<20 mmHg) for clinical improvement was reached in the MgSO 4 and sildenafil group at the third and the second day of the therapy, respectively. In the sildenafil group, PAP values were found to be significantly lower (Fig. 3) . Regarding the adverse effects of the treatment, the MgSO 4 group was found to receive more inotropic support reaching statistical significance ( p ¼ 0.002). In the MgSO 4 group, MBP values were found significantly lower at the second and third hours of the therapy (Fig. 4) . Grade I ICH was observed in two patients in MgSO 4 group and one in sildenafil group before vasodilator treatment. Gastrointestinal bleeding developed in three patients in the sildenafil group and two patients in the MgSO 4 group at the beginning of treatment (first 24 h). Three patients with gastrointestinal bleeding in the sildenafil group were excluded from the study, since their enteral feedings were stopped. After the treatment, any additional medical problems (i.e. progression of hemorrhage, allergic reaction, rash, arrythmia, cardiac dysfunction, shock, abdominal distention, bleeding from the urinary tract or endotracheal tube, sepsis, metabolic abnormality) were not observed. All the newborns had normal auditory screening test, neurological and ophtalmological examination at discharge.
Discussion
There are several studies suggesting the benefits of vasodilator agents like magnesium and sildenafil in PPHN when ECMO, iNO and HFOV therapies are not available [15] [16] [17] . Magnesium and sildenafil which are shown to have a pulmonary vasodilatator effect was studied in animal and human models with pulmonary hypertension [17] [18] [19] [20] .
All the studies using magnesium showed a significant improvement in OI, but only in two studies, the time for OI improvement was reported to be 24 h from the beginning of treatment [19, 21] . However, Steinhorn et al. [22] observed a significant improvement in OI after 4 h and Baquero et al. [4] obtained an OI improvement after 6 h of oral sildenafil treatment. Our study suggests that OI improvement (OI <15) is early in sildenafil group (36 vs. 60 h). In sildenafil group, OI was found to be significantly lower after 12 h of the treatment. But supporting our hypothesis, the difference in average OI between groups was found to be >5 only at 36 h of treatment.
As far as we know, this is the first study to show the change of PAP values after MgSO 4 or sildenafil treatment in neonates with PPHN. In an animal study it has been reported that intratracheal sildenafil induced a rapid decrease in PAP, which was established to develop in 2-120 min in newborn piglets [23] . In our study, PAP improvement was obtained early in sildenafil group (2 vs. 3 days).
In uncontrolled studies, the reported mean ventilation duration was 5.5-11.8 days for PPHN treatment with magnesium [13, 19, 24] . However there was no data with sildenafil. Ventilation duration was found to be longer in MgSO 4 group (6 vs. 4 days) in our study. This was probably due to magnesium effects like sedation and muscle relaxation.
Hypotensive effect of MgSO 4 is well known in treatment of PPHN [16] . Sildenafil has been shown to decrease the MBP by 25% in conscious rats [25] . Many patients received inotropic support since the target value was accepted as the 50th percentile for MAP in our study. On the other hand, in the MgSO 4 group the higher number of patients receiving inotropic support may suggest that the possible systemic hypotensive effects of MgSO 4 were higher than sildenafil.
This study has some important limitations. First, the blood concentration of sildenafil was not Conclusion According to our knowledge, this is the first study which compares the effects of MgSO 4 and sildenafil treatments in the PPHN. This study suggests that IV MgSO 4 and oral sildenafil may be alternative treatments for PPHN in NICU without iNO facilities. Although among two groups the difference in OI >5 as speculated in our hypothesis could not be found, sildenafil was more effective than MgSO 4 in terms of the time for OI and PAP improvement, ventilation duration and support of inotropic agent. Further studies are needed to confirm this assumption and to establish the long-term side effects of both drugs in the future in order to suggest oral sildenafil or intravenous MgSO 4 as an alternative treatment when the other treatment modalities are not available. 
